Q4-FY26 · Yogesh Agrawal
Our revenue from operations grew by 21%. While margins grew by 18%. Reflecting strong operating performance alongside continued investments to support future growth.
AJANTAPHARMA / language trends
Read confidence between the lines.
Ajanta Pharma · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Yogesh Agrawal
We are looking at a mid single digit growth for the US business considering that for the whole year we have delivered a extremely robust growth of 49%.
Q4-FY26 · Rajeev Shakdher
Our new product contribution within that is 4.7% out of 13%. As against the industry which stands at 2.8% out of 10%.